Compare
Organon & Co. vs Perrigo Co PLC vs Zoetis Inc. vs Viatris Inc
| Latest fiscal year | Organon & Co. OGN | Perrigo Co PLC PRGO | Zoetis Inc. ZTS | Viatris Inc VTRS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $6.22B | $4.25B | $9.47B | $14.30B |
| Revenue growth (YoY) | -2.9% | -2.8% | +2.3% | -3.0% |
| Gross margin | 53.3% | 35.1% | 71.8% (computed) | 35.1% |
| Operating margin | n/a | -26.4% | n/a | -18.6% |
| Net margin | 3.0% | -33.5% | 28.2% | -24.6% |
| Net income | $187.00M | -$1.43B | $2.67B | -$3.51B |
| EPS (Diluted) | $0.72 | -$10.29 | $6.02 | -$3.00 |
| Operating cash flow | $700.00M | $238.50M | $2.90B | $2.32B |
| Free cash flow | $538.00M | $145.10M | $2.28B | $1.94B |
| Cash & equivalents | $574.00M | n/a | n/a | $1.32B |
| Total assets | $12.87B | $8.54B | $15.47B | $37.19B |
| Total liabilities | $12.12B | $5.60B | $12.14B | $22.48B |
| Shareholders' equity | $752.00M | $2.94B | $3.33B | $14.71B |
| Return on year-end equity | 24.9% | -48.6% | 80.2% | -23.9% |
| Shares outstanding | 260.32M | 137.60M | 424.93M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Organon & Co. | Perrigo Co PLC | Zoetis Inc. | Viatris Inc |
|---|---|---|---|---|
| Latest | $6.22B Ended 2025-12-31 | $4.25B Ended 2025-12-31 | $9.47B Ended 2025-12-31 | $14.30B Ended 2025-12-31 |
| 1 year earlier | $6.40B Ended 2024-12-31 | $4.37B Ended 2024-12-31 | $9.26B Ended 2024-12-31 | $14.74B Ended 2024-12-31 |
| 2 years earlier | $6.26B Ended 2023-12-31 | $4.66B Ended 2023-12-31 | $8.54B Ended 2023-12-31 | $15.43B Ended 2023-12-31 |
| 3 years earlier | $6.17B Ended 2022-12-31 | $4.45B Ended 2022-12-31 | $8.08B Ended 2022-12-31 | $16.26B Ended 2022-12-31 |
| 4 years earlier | $6.30B Ended 2021-12-31 | $4.14B Ended 2021-12-31 | $7.78B Ended 2021-12-31 | $17.89B Ended 2021-12-31 |